Novel rat model of multiple mitochondrial dysfunction syndromes (MMDS) complicated with cardiomyopathy

Yahao Ling1 | Jiaxin Ma2 | Xiaolong Qi2 | Xu Zhang2 | Qi Kong2 | Feifei Guan2 | Wei Dong1 | Wei Chen1 | Shan Gao1 | Xiang Gao1 | Shuo Pan2 | Yuanwu Ma1 | Dan Lu2 | Lianfeng Zhang1

Abstract

Background: Multiple mitochondrial dysfunction syndromes (MMDS) presents as complex mitochondrial damage, thus impairing a variety of metabolic pathways. Heart dysplasia has been reported in MMDS patients; however, the specific clinical symptoms and pathogenesis remain unclear. More urgently, there is a lack of an animal model to aid research. Therefore, we selected a reported MMDS causal gene, Isca1, and established an animal model of MMDS complicated with cardiac dysplasia.

Methods: The myocardium-specific Isca1 knockout heterozygote (Isca1 HET) rat was obtained by crossing the Isca1 conditional knockout (Isca1 cKO) rat with the α myosin heavy chain Cre (α-MHC-Cre) rat. Cardiac development characteristics were determined by ECG, blood pressure measurement, echocardiography and histopathological analysis. The responsiveness to pathological stimuli were observed through adriamycin treatment. Mitochondria and metabolism disorder were determined by activity analysis of mitochondrial respiratory chain complex and ATP production in myocardium.

Results: ISCA1 expression in myocardium exhibited a semizygous effect. Isca1 HET rats exhibited dilated cardiomyopathy characteristics, including thin-walled ventricles, larger chambers, cardiac dysfunction and myocardium fibrosis. Downregulated ISCA1 led to deteriorating cardiac pathological processes at the global and organizational levels. Meanwhile, HET rats exhibited typical MMDS characteristics, including damaged mitochondrial morphology and enzyme activity for mitochondrial respiratory chain complexes I, II and IV, and impaired ATP production.

Conclusion: We have established a rat model of MMDS complicated with cardiomyopathy, it can also be used as model of myocardial energy metabolism dysfunction and mitochondrial cardiomyopathy. This model can be applied to the study of the mechanism of energy metabolism in cardiovascular diseases, as well as research and development of drugs.
**1 | INTRODUCTION**

Multiple mitochondrial dysfunction syndromes (MMDS) presents as impaired mitochondrial metabolism and energy production, which can ultimately lead to damage to both the structure and function of mitochondrial complex, and thus the function of mitochondrial respiratory complex. MMDS is accompanied by serious damage to various metabolic pathways, resulting in conditions such as mitochondrial encephalopathy, myopathy and respiratory insufficiency. Energy generation impairment is considered as the pathogenic basis of MMDS. It has been reported that mutations in genes involved in synthesis of ISC may seriously damage mitochondrial metabolic processes and thus ultimately disrupt energy production. Mutated genes that have been reported include BOLA3, IBA57, ISCA1 and PMP12. Abnormal muscle or heart development has been reported in patients with MMDS. BOLA3 deficient patients developed cardiomyopathy, and IBA57 deficient patient developed severe myopathy. ISCA1 deficiency results in spasticity with exaggerated deep tendon reflexes, while PMP12 deficient patients develop dystonia. The human heart is a very energy-intensive tissue and mitochondrial oxidative phosphorylation is responsible for almost all of the ATP production (>95%) in adult mammalian hearts. Therefore, maintaining mitochondrial function is essential for the functioning of the cardiac pump.

However, the specific mechanism by which MMDS induces cardiac developmental disorders is not yet well understood, and there is an urgent need for suitable in vivo animal models to aid research. ISCA1 is the A-type ISC protein, which is part of the mitochondrial [4Fe–4S] cluster assembly machinery of key respiratory enzymes. Two variants have been reported, p.(Glu87Lys) and p.(Tyr101Cys), and ISCA1-related MMDS results mainly in metabolic disorders, neurodevelopmental damage and cardiomyopathy. We next analyzed the expression of ISCA1 within the GSE1869 dataset from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo), and we found that it increased significantly in patients with MMDS. BOLA3 deficient patients developed cardiomyopathy, energy metabolism, ISCA1, multiple mitochondrial dysfunction syndromes (MMDS), rat model

**2 | METHODS**

### 2.1 Generation of myocardium specific Isca1 knockout rats

The Isca1-floxed rats (referred to as Isca1 conditional knockout, Isca1 cKO) were produced using the CRISPR/Cas9 system. The rats produced were confirmed as Isca1 cKO by sequencing and genotyping with specific primers (Table S1). Animals carrying the α-MHC-Cre gene were identified using PCR analysis of tissue genomic DNA using Cre-specific primers (Table S1). Myocardium specific Isca1 knockout heterozygote rats were generated using the Cre-loxP system by crossing Isca1 cKO rats with α-MHC-Cre rats. Offspring with the genotype of positive α-MHC-Cre transgene and Isca1(lox/+) were selected as myocardium specific Isca1 knockout heterozygote (Isca1(lox/+)α-MHC-Cre) rats and are referred to as Isca1 HET rats in this manuscript (Figure 1C). The Isca1 HET rats were used in subsequent analyses and WT littermates were used as controls. Further information on the rats used in this study can be found in our rat database (www.ratresource.com).

The background strain of the rats used in this study was the Sprague-Dawley rat. All rats were maintained in standard cages in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited animal facility. All animal experiments were approved by the Animal Care and Use Committee of the Institute of Laboratory Animal Science of Peking Union Medical College (Permission No. MYW20002).

### 2.2 Genomic DNA preparation and genotyping

The EasyPure® Genomic DNA Kit (China, Trans Gen Biotech, EE101-22) was used to extract genomic DNA from the tail tissue of 7-day-old rats according to the manufacturer’s instructions. The rat tail tissue was disaggregated by incubating the tissue in a lysis buffer with protease K (20 mg/ml) in a swing bed at 55°C for 6–8 h. A silica-based column specifically for binding DNA was used to separate the genomic DNA from the tissue lysate. The genomic DNA was eluted by adding 150 μl of elution buffer.

### 2.3 Measurement of basic physiological parameters

Blood pressure (BP) was measured by the tail-cuff method (Visitech Systems, BP-2000, USA) in conscious rats (3 times per week). Weekly BP data are the average of three measurements per week.
taken at 10:00 a.m. For electrocardiography determination, the rats were first anesthetized with isoflurane (1.5%–2.5%) and then held in a supine position, using a heating pad to maintain body temperature. The limb leads were placed subcutaneously with lead II derivation. Traces were recorded using BIOPAC system (MP150, USA) and analyzed using the Acqknowledge software (USA).19

2.4 Survival analysis

The cumulative death rates of the WT littermate control rats and the Isca1 HET rats (Isca1^{floxed}/α-MHC-Cre) were calculated from birth to 18 months of age. A pathologist performed the autopsy after the death of each rat and pathological changes and morphological alterations of the heart were recorded. The Kaplan–Meier curves were compared using the log-rank test (GraphPad Prism8 software).20

2.5 Adriamycin treatment

Two-month-old rats were used for Adriamycin (ADR) treatment. ADR was injected intraperitoneally in a constant volume of saline at 2.5 mg/kg every other day for a total of 2 weeks as previously reported.21,22 The saline groups received the same volume of saline. Echocardiography was performed on all rats on day 0 (the day before ADR treatment). All surviving rats were subjected to follow-up echocardiography at 3 months of age (2 weeks after the cessation of ADR treatment) and used for subsequent analysis.

2.6 Echocardiography

The echocardiographic inspection was performed using a small animal echocardiography analysis system (Vevo770 and Vevo3100, Canada) as previously described.20,22 The parameters of the left
ventricular (LV) diameter (LVID) and LV anterior wall (LVAW) at end-diastole and end-systole, and LV ejection fraction (LVEF) and LV percentage fractional shortening (LVFS) were measured. The mean value of at least three continuous cardiac cycles was recorded.

2.7 | Histological analysis

Cardiac tissues were fixed with formaldehyde (4%), mounted in paraffin and then sectioned (3–4 μm in thickness) using a Tissue-Tek6 Sledge microtome (IVS-410, SAKURA, Japan). The sections were first stained with H&E and then observed under a light microscope (NanoZoomer S60, C13210, Hamamatsu Photonics, Japan) as previously described.20,21 All sections were analyzed using the NDP.view2 image viewing software. For the transmission electron microscopy (TEM) analysis, cardiac tissues were routinely fixed in glutaraldehyde (2.5%) and phosphate buffer (0.1 M, pH 7.4), and then fixed in osmium tetroxide buffer (1%) for 1 h. The sections were examined under a JEM-1230 TEM after uranyl acetate and lead citrate staining as described previously.18,21

2.8 | Protein extraction and immunoblotting

Total protein lysates were prepared from rat heart tissues using protein extraction reagent (USA, Thermo, 78510) as described previously.21,23 A mitochondria/cytosol fractionation kit (UK, Abcam, ab65320) was used for isolation of mitochondrial and cytosolic fractions from cardiac tissues, following the instructions in the manual.24 Protein extracts were first separated through SDS-PAGE and then transferred to nitrocellulose membranes. The membranes were incubated at 4°C overnight with appropriate primary antibodies (ISCA1 [USA, Thermo, PA5-60121]; TOMM20 [USA, Thermo, PA5-52843]; NDUFA9 [UK, Abcam, ab14713]; NDUFS3 [UK, Abcam, ab110246]; SDHB [UK, Abcam, ab14714]; GAPDH [UK, Abcam, ab201822]) and subsequently kept for 1 h at RT with the appropriate secondary antibodies. Western blot images were acquired (Bio-Rad, ChemiDoc XRS+Gel Imaging System, USA) and quantitatively analyzed with Image J software.

2.9 | Measurement of mitochondrial respiratory complex enzyme activity

Activity analysis of mitochondrial respiratory complexes I, II and IV were performed using enzyme assay kits (UK, Abcam, ab109721, ab109908, ab109911) according to the manufacturer’s protocols, as previous described.25 In brief, 30 mg of heart tissue from rats were homogenized for harvesting the extracts of mitochondria. Microplate wells were precoated with specific capture antibodies for measuring the activity of complexes I, II and IV. The samples were then added to the microplate wells to capture enzyme activity and incubated. Enzyme activities were measured using a colorimetric method.

2.10 | ATP measurement

An ATP assay kit (USA, Biovision, K354-100) was used for measurement of myocardial ATP content as previous described.26 Briefly, 40 mg of cardiac tissues from rats were homogenized in 400 μl of ATP assay buffer and deproteinized using a deproteinizing sample preparation kit (UK, Abcam, ab204708). The standard curve was prepared based on the colorimetric assay and the absorbance was assayed in a micro-plate reader at 570 nm.

2.11 | Statistical analysis

The experimental data are expressed as means ± SD and analyzed with unpaired two-tailed Student’s t tests for two groups or one-way analysis of variance (ANOVA, with Tukey correction) for multiple groups. GraphPad Prism8 software is used for statistical analysis and p < .05 was considered significant.

3 | RESULTS

3.1 | Generation of myocardium-specific Isca1 knockout heterozygote and observation of basic physiological parameters

The Isca1 conditional knockout (Isca1 cKO) rat and the α-MHC-Cre transgenic rats were established in our lab. Further information can be found in our rat database (www.ratresource.com). The myocardium-specific Isca1 knockout heterozygote (referred as Isca1 HET) rats were obtained by crossing Isca1 cKO rats with the α-MHC-Cre rats (Figure 1C). Genotyping was carried out by PCR and Isca1fox7/α-MHC-Cre (with loxp band at 1401 bp and wt band at 1333 bp, and Cre gene positive) rats and WT littersmates were used in our subsequent studies (Figure 1D). The protein expression level was confirmed by western blot and ISCA1 protein knockdown efficiency reached 46.3% in myocardial tissues (Figure 1E,F, n = 3 rats per group, p < .05 vs. WT).

We then performed general observations on rats at 6 months of age and determined several main physiological parameters, including body weight, water and food intake, BP and ECG parameters. The HET rats exhibited no difference compared with the WT rats in these parameters, including systolic pressure, diastolic pressure, mean BP, QRS complex and QTc interval duration (Table 1).

3.2 | Isca1 HET rats exhibited a typical pathological phenotype of DCM

To study the effects of ISCA1 knockdown expression on geometry and function of heart, we performed echocardiography on HET and WT rats at 1, 3, 5, 7 and 10 months of age. We found that the Isca1
HET rats exhibited DCM characteristics, including thin-walled ventricles, larger chambers, and cardiac dysfunction from 3 months of age. This was demonstrated by decreased left ventricle (LV) anterior wall thickness (LVAW) and LV posterior wall thickness (LVPW), increased LV diameter (LVID) both at end-systole and end-diastole, and decreased LV ejection fraction (LVEF) and LV fractional shortening (LVFS) (Figure 2A–I, n = 10–12 in WT group and n = 8–13 in HET group, p < .05, p < .01 vs. WT).

The morphological phenotypes of DCM in ISCA1 HET rats at 6 months of age were further confirmed by histological observation, including H&E and Masson staining. We found myocardium breakdown and lysis, and myocardium fibrosis in ISCA1 HET rats (Figure 2J).

We then performed survival rate observations. Cumulative rat mortality data from WT and HET groups were recorded. There were no deaths in the WT group (n = 15); however, the survival rate was 83.3% in HET group (n = 12) at the end of the observation period (18 months of age) (Figure 3A). The gross anatomy of the dead HET rats revealed dilated ventricles, thin wall thickness and congestion in the ventricles. The characteristics of mitochondrial and metabolic disorders and cardiomyopathy phenotypes in HET rat is summarized in Figure 2L.

### 3.3 Downregulated Isca1 leads to deterioration of cardiac pathological processes at the global and organizational levels

Subsequently, we treated the HET and WT rats with ADR to assess their response to stress.

The WT-ADR rats exhibited DCM/heart failure (HF) phenotypes induced by ADR treatment, as demonstrated by the decreased LVAWS and LVPWS both at end-systole and end-diastole (Figure 3A–E, p < .05 vs. WT-saline) at the end of observation (2 weeks after cessation of ADR treatment). While LVID exhibited no difference at the end of observation (Figure 3F–G). Cardiac function was also impaired in the WT-ADR group, as demonstrated by the decreased LVEF and LVFS (Figure 3H–I, p < .05 vs. WT-saline).

We found that ISCA1 knockdown expression exacerbated cardiac geometry disruption and dysfunction under ADR treatment. LVAWS and LVPWS decreased 12.4% and 13.6%, and LVIDS increased 8.5%, respectively, in WT-ADR group compared with the WT-saline group; however, those parameters changed to 17.1%, 17.6% and 10.4%, respectively, in the HET-ADR group compared with the HET-saline group. LVEF decreased 13.9% in the WT-ADR group compared with the WT-saline group, while it decreased 17.63% in the HET-ADR group compared with the HET-saline group (Figure 3B–I).

After assessing changes in cardiac geometry and function, pathological changes in response to ADR-induced stress were further detected in WT and HET groups by H&E and Masson staining and transmission electron microscopy (TEM). The thinning wall, dilated chamber and malalignment in WT-ADR rats were further damaged by ISCA1 knockdown expression in the HET-ADR group, consistent with the gross morphological observations obtained by echocardiography. Collagen accumulation in the interstitial space, myocardiolysis and swollen mitochondria were also aggravated in the HET-ADR group compared with the WT-ADR group (Figure 3J).

### 3.4 Isca1 HET rats exhibited complex mitochondrial damage affecting both structure and function in myocardium

To detect the typical characteristics of MMDS in myocardium from our HET rats, we first detected the mitochondrial morphological changes through TEM. Poorly organized myocardium and myocardiolysis, and swollen mitochondria with damaged membrane structure and partial absence of crests were observed in myocardium from HET rats at 6 months of age (Figure 4A).

We subsequently measured the expression levels of key proteins and enzyme activity for complex I, II and IV in HET rats. We found, using western blots, that the mitochondrial complex I subunit, including the ubiquinone oxidoreductase subunit A9 (NDUFA9) and the ubiquinone oxidoreductase core subunit S3 (NDUFS3), and the complex II subunit succinate dehydrogenase complex iron sulfur subunit

| Group | Number | WT | KO |
|-------|--------|----|----|
| Body weight (g) | 452.25 ± 132.08 | 389.13 ± 48.93 |
| Water intake (ml) | 15.88 ± 3.82 | 16.06 ± 2.65 |
| Food intake (g) | 25.09 ± 3.49 | 26.63 ± 3.37 |
| Systolic pressure (mmHg) | 133.60 ± 14.43 | 127.03 ± 13.55 |
| Diastolic pressure (mmHg) | 64.937 ± 15.297 | 64.080 ± 9.222 |
| Mean blood pressure (mmHg) | 88.00 ± 14.56 | 85.15 ± 9.05 |
| QRS complex (s) | 0.047 ± 0.005 | 0.045 ± 0.005 |
| QTc interval duration (s) | 0.080 ± 0.006 | 0.077 ± 0.005 |

---

**Table 1** The main physiological parameter of Isca1 HET rats at 6 months of age.
B (SDHB), were obviously decreased in myocardium from HET rats (Figure 4B–E, \( p < .01, ** p < .001, *** p < .001, \) vs. WT group). The enzyme activity of complexes I, II and IV also decreased significantly in myocardium from HET rats (Figure 4F–H, \( p < .01, ** p < .001, \) vs. WT group). We also measured ATP generation, and the concentration decreased significantly in myocardium from HET rats (Figure 4I, \( p < .01, \) vs. WT group). These data showed that decreased ISCA1 expression severely damaged the mitochondrial complex and impaired energy generation in myocardium.

**FIGURE 2**. *Isca1* HET rats exhibited a typical pathological phenotype of DCM. (A) The M-mode echocardiography screenshot of rats at 6 months of age. (B–I) Echocardiographic parameters LVAWS, LVAWD, LVPWS, LVPWD, LVDS, LVIDD, EF and FS were analyzed at 1, 3, 6, 9, 12, 18 months (‘\( p < .05, ** p < .01, *** p < .001, \) vs. WT). (J) Representative photographs of whole-heart longitudinal sections with H&E staining (scale bar = 5 mm), magnification of H&E and Masson trichrome-stained sections of the left ventricle (scale bar = 20 \( \mu \)m) from two groups at 6 months of age. (K) Cumulative percentage survival rate for WT (\( n = 15 \)) and HET (\( n = 12 \)) groups were calculated from 1 to 18 months. (L) Schematic diagram of phenotypic development in HET rats.
The heart is highly dependent on mitochondrial metabolism to meet its enormous energy requirements. According to research findings, >40% of the cytoplasmic space in adult cardiac myocytes is occupied by mitochondria. Maintaining a healthy mitochondrial population is of paramount importance for cardiac homeostasis, since damaged mitochondria produce less ATP and generate...
dangerous amounts of reactive oxygen species (ROS), ultimately leading to multiple cardiovascular diseases. Mitochondrial injury is associated with various cardiovascular diseases (CVDs), such as hypertension, atherosclerosis, ischemia-reperfusion (I/R) injury, metabolic and genetic cardiomyopathies, heart failure and ischemic stroke. However, the specific mechanism whereby mitochondrial dysfunction induces cardiac developmental disorders and multiple cardiovascular diseases is not yet well understood, and there is an urgent need for suitable in vivo animal models to aid research.

Mutations in the genes involved in synthesis of ISC may severely impair diverse mitochondrial metabolic pathways and interfere with energy production, and gene mutations involved in ISC synthesis are closely related to MMDS. Furthermore, abnormal muscle or heart development has been observed in MMDS, and among the genes involved in this disease, abnormal ISCA1 has been shown to cause a subtype of the disease, MMDS. So far, two variants have been reported, p.(Glu87Lys) and p.(Tyr101Cys), and clinical symptoms are reported in patients carrying pathogenic variants of ISCA1, including white matter abnormalities, early onset neurological deterioration, seizures, dilated ventricles, etc.

Our results demonstrated that our HET model rats exhibited typical pathological phenotypes of DCM, and downregulated ISCA1 exacerbated cardiac pathological process under stress. We also recorded destruction of mitochondrial structure and function in myocardium with ISCA1 deficiency. Therefore, our findings are consistent with the mitochondrial damage and cardiomyopathy phenotypes found in clinical patients with Isca1 mutations.

Myocardium specific Isca1 knockout heterozygote rats were generated using the Cre-loxP system by crossing Isca1 cKO rats with α-MHC-Cre rats. Offspring with a positive α-MHC-Cre transgene and Isca1<sup>flox/+</sup> genotype were selected as myocardium specific Isca1 knockout heterozygote (Isca1<sup>flox/+</sup>/α-MHC-Cre) rats. Currently, the knockout heterozygote model exhibits two recognized advantages. First, the homozygous phenotype is severe and death occurs in early childhood. Premature death of the homozygote makes it unsuitable for the study of heart disease and mitochondrial metabolism in adults. However, the longer survival of the heterozygotes is
beneficial for carrying out research related to drug efficacy and development. In addition, heterozygous rats are easy to reproduce and are thus more readily available. Therefore, they are more suitable for use in the large-scale screening and research and development of related drugs.

In this study, our established myocardium specific lso1 knock-out heterozygote rats exhibited typical pathological phenotypes of DCM and complex mitochondrial damage in both structure and function in myocardium. Therefore, this rat model can be applied to multiple research areas, including abnormal energy metabolism, mitochondrial morphology damage, mitochondrial dysfunction and cardiomyopathy. Consequently, the model can also be used to investigate the pathogenesis of the above related diseases and drug development.

ACKNOWLEDGEMENTS
The present work was supported in part by the Beijing Natural Science Foundation (5212017), CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-015) and National Natural Science Foundation (31872314 and 31970508).

CONFLICT OF INTEREST
None.

AUTHOR CONTRIBUTIONS
All listed authors meet the requirements for authorship. LFZ and DL conceived and designed the experiments and wrote the main manuscript text. YHL performed most of the experiments. YWM and XZ contributed to the measurement of complex activity. XLQ contributed to the measurement of physiological parameters. SG, XG and FFG contributed to the measurement of echocardiographic parameters. JXM and SP contributed to the animal breeding and management. WC contributed to microinjection technique. WD contributed to establishment of the animal models and sequence analysis. WC contributed to microinjection technique. WD contributed to measurement of echocardiographic parameters. SG, XG and FFG contributed to the measurement of physiological parameters. XLQ contributed to the measurement of complex activity.

ORCID
Yuanwu Ma https://orcid.org/0000-0002-1882-1777

REFERENCES
1. Ahting U, Mayr JA, Vanlander AV, et al. Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency. Front Genet. 2015;6:123.
2. Al-Hassnan ZN, Al-Dosary M, Alfadhel M, et al. ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder. J Med Genet. 2015;52(3):186-194.
3. Cameron J, Janer A, Levandovskiy V, et al. Mutations in iron-sulfur cluster scaffold genes NFU1 and BOLA3 cause a fatal deficiency of multiple respiratory chain and 2-oxoacid dehydrogenase enzymes. Am J Hum Genet. 2011;89(4):486-495.
4. Stehling O, Wilbrecht C, Lilli R. Mitochondrial iron–sulfur protein biogenesis and human disease. Biochimie. 2014;100:61-77.
5. Ahting U, Mayr JA, Vanlander AV, et al. Clinical, biochemical, and genetic spectrum of seven patients with NFU1 deficiency. Front Genet. 2015;6:123.
6. Al-Hassnan ZN, Al-Dosary M, Alfadhel M, et al. ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder. J Med Genet. 2015;52(3):186-194.
7. Shukla A, Hebarb M, Srivastava A. Homozygous p.(Glu87Lys) variant in ISCA1 is associated with a multiple mitochondrial dysfunctions syndrome. J Hum Genet. 2017;62(7):723-727.
8. Vögtle-FN, Brändli B, Larson A, et al. Mutations in PMPCB encoding the catalytic subunit of the mitochondrial precursor protease cause neurodegeneration in early childhood. Am J Hum Genet. 2018;102(4):557-573.
9. Nishioka M, Inaba Y, Motobayashi M, et al. An infant case of diffuse cerebrospinal lesions and cardiomyopathy caused by BOLA3 mutation. Brain Dev. 2018;40(6):484-488.
10. Beilschmidt LK, Puccio HM. Mammalian Fe–S cluster biogenesis and its implication in disease. Biochimie. 2014;100:48-60.
11. Shukla A, Kaur P, Girisha KM. Report of the third family with multiple mitochondrial dysfunctions syndrome 5 caused by the founder variant p.(Glu87Lys) in ISCA1. J Pediatr Genet. 2018;7(3):130-133.
12. Torraco A, Stelinger O, Stümpfig C, et al. ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe–4S] proteins. Hum Mol Genet. 2018;27(15):2739-2754.
13. Morales PE, Arias-Durán C, Ávalos-Guajardo Y, et al. Emerging role of mitophagy in cardiovascular physiology and pathology. Mol Aspects Med. 2020;71:100822.
14. Tong M, Sadowshima J. Mitochondrial autophagy in cardiomyopathy. Curr Opin Genet Dev. 2016;38:8-15.
15. Sheftel AD, Wilbrecht C, Stelinger O, et al. The human mitochondrial ISCA1, ISCA2, and IBASA7 proteins are required for [4Fe–4S] protein maturation. Mol Biol Cell. 2012;23(7):1157-1166.
16. Ma Y, Zhang XU, Shen B, et al. Generating rats with conditional alleles using CRISPR/Cas9. Cell Res. 2014;24(1):122-125.
17. Ma Y, Yu L, Pan S, et al. CRISPR/Cas9-mediated targeting of the Rosas26 locus produces Cre reporter rat strains for monitoring Cre-loxP-mediated lineage tracing. FEBS J. 2017;284(19):3262-3277.
18. Wu T-T, Ma Y-W, Zhang XU, et al. Myocardial tissue-specific Dnm1 knockout in rats protects against pathological injury induced by Adriamycin. Lab Invest. 2020;100(7):974-985.
19. Lu D, Lian H, Zhang X, et al. LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice. PLoS One. 2010;5(12):e15167.
20. Lu D, Wang J, Li J, et al. Mox1 accelerates myocardial hypertrophic degeneration through Gata4. Cardiovasc Res. 2018;114(2):300-311.
21. Lu D, Ma Y, Zhang W, et al. Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnTR141W dilated cardiomyopathy transgenic mice. Lab Invest. 2010;90(1):81-89.
22. Guan F, Yang X, Li J, et al. New molecular mechanism underlying Myc-mediated cytochrome P450 2E1 upregulation in apoptosis and energy metabolism in the myocardium. J Am Heart Assoc. 2019;8(1):e009871.
23. Redondo-Angulo I, Mas-Stachurska A, Sitges M, Giralt M, Villarroga F, Planavila A. C/EBPβ is required in pregnancy-induced cardiac hypertrophy. Int J Cardiol. 2016;202:819-828.
24. Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020;5(9):e132747.
25. Yao X, Wiggington JG, Maass DL, et al. Estrogen-protected cardiac protection following burn trauma is mediated through a reduction in mitochondria-derived DAMPs. Am J Physiol Heart Circ Physiol. 2014;306(6):882-894.
26. Hasumi Y, Baba M, Hasumi H, et al. Folliculin (Ficn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Hum Mol Genet. 2014;23(21):5706-5719.
27. Hom J, Sheu S-S. Morphological dynamics of mitochondria—a special emphasis on cardiac muscle cells. J Mol Cell Cardiol. 2009;46(6):811-820.
28. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. *Annu Rev Physiol*. 2010;72:19-44.

29. Tan Y, Mui D, Toan S, Zhu P, Li R, Zhou H. SERCA overexpression improves mitochondrial quality control and attenuates cardiac microvascular ischemia-reperfusion injury. *Mol Ther Nucleic Acids*. 2020;22:696-707.

30. Wang J, Toan S, Zhou H. Mitochondrial quality control in cardiac microvascular ischemia-reperfusion injury: new insights into the mechanisms and therapeutic potentials. *Pharmacol Res*. 2020;156:104771.

31. Wang J, Zhou H. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury. *Acta Pharmacologica Sinica B*. 2020;10(10):1866-1879.

32. Forte M, Schirone L, Ameri P, et al. The role of mitochondrial dynamics in cardiovascular diseases. *Br J Pharmacol*. 2021;178(10):2060-2076.

33. Vásquez-Trincado C, García-Carvajal I, Pennanen C, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J Physiol*. 2016;594(3):509-525.

34. Tan Y, Xia F, Li L, et al. Novel insights into the molecular features and regulatory mechanisms of mitochondrial dynamic disorder in the pathogenesis of cardiovascular disease. *Oxid Med Cell Longev*. 2021;2021:2-11.

35. Zhou H, Zhu P, Wang J, Zhu H, Ren J, Chen Y. Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy. *Cell Death Differ*. 2018;25(6):1080-1093.

36. Wang J, Toan S, Zhou H. New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. *Angiogenesis*. 2020;23(3):299-314.

37. Zhou H, Toan S, Zhu P, Wang J, Ren J, Zhang Y. DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis. *Basic Res Cardiol*. 2020;115(2):1-17.

38. Uzarska MA, Nasta V, Weiler BD, et al. Mitochondrial BoI1 and BoI3 function as assembly factors for specific iron-sulfur proteins. *eLife*. 2016;5:e16673.

39. Lebigot E, Hully M, Amazit L, et al. Expanding the phenotype of mitochondrial disease: novel pathogenic variant in ISCA1 leading to instability of the iron-sulfur cluster in the protein. *Mitochondrion*. 2020;52:75-82.

40. Finsterer J, Zarrouk-Mahjoub S. A commentary on homozygous p.(Glu87Lys) variant in ISCA1 is associated with a multiple mitochondrial dysfunctions syndrome. *J Hum Genet*. 2017;62(9):865-866.

41. Shukla A, Hebbar M, Girisha KM. A reply to a commentary on homozygous p.(Glu87Lys) variant in ISCA1 is associated with a multiple mitochondrial dysfunctions syndrome. *J Hum Genet*. 2017;62(9):867.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Ling Y, Ma J, Qi X, et al. Novel rat model of multiple mitochondrial dysfunction syndromes (MMDS) complicated with cardiomyopathy. *Anim Models Exp Med*. 2021;4:381-390. doi:10.1002/ame2.12193